Skip to main content
. 2010 Dec;51(12):6566–6574. doi: 10.1167/iovs.10-6161

Figure 3.

Figure 3.

Effect of anti-CD8 antibody treatment on ACAID and corneal allograft survival. (A) Mice were treated with 500 μg anti-CD8 or isotype control on days −3 and −4. ACAID was induced on day 0 with C57BL/6 splenic nonadherent cells. Subcutaneous injections of C57BL/6 splenocytes were given on day +7. DTH challenge with mitomycin C–treated C57BL/6 cells was on day +14. Negative control animals received an ear challenge only (n = 5 mice for each group). This experiment was performed 3 times with similar results. (B) BALB/c hosts were treated with 500 μg anti-CD8 1 week before and once weekly after allograft transplantation. Sixty percent of BALB/c hosts treated with anti-CD8 rejected their C57BL/6 corneal allografts with a MST of 52 days (n = 10). The incidence of C57BL/6 corneal allograft rejection in BALB/c mice treated isotype control was 50% (n = 10) and with an MST of 46 days (P > 0.05).